Volume 14 Supplement 1
Edited by Mark Powers
Unrestricted educational grants for the development of these guidelines and publication of this supplement were provided by Astra Zeneca Canada, Eli-Lilly Canada, Janssen Inc, Lundbeck Canada, Pfizer Canada, Purdue Canada, Servier Canada Inc, Shire Canada and Valeant Canada. None of the members received payment for participating in the development of these guidelines. The article has undergone the journal's standard peer review process for supplements. The Supplement Editor is funded by a grant from the National Institute on Drug Abuse K01 DA035930 and declares that he has no other competing interests.
Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.
Citation Impact 2023
Journal Impact Factor: 3.4
5-year Journal Impact Factor: 4.2
Source Normalized Impact per Paper (SNIP): 1.374
SCImago Journal Rank (SJR): 1.301
Speed 2023
Submission to first editorial decision (median days): 24
Submission to acceptance (median days): 146
Usage 2023
Downloads: 8,228,380
Altmetric mentions: 7,538
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication
More information is available here